sibutramine has been researched along with Bipolar Disorder in 8 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 9.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Minimal recommended dose of sibutramine induced manic episode that was the first manifestation of bipolar disorder." | 7.78 | Sibutramine-induced mania as the first manifestation of bipolar disorder. ( Simonienko, K; Szajda, SD; Szulc, A; Waszkiewicz, N; Zalewska, A; Zalewska-Szajda, B; Zwierz, K; Ładny, JR, 2012) |
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 5.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Minimal recommended dose of sibutramine induced manic episode that was the first manifestation of bipolar disorder." | 3.78 | Sibutramine-induced mania as the first manifestation of bipolar disorder. ( Simonienko, K; Szajda, SD; Szulc, A; Waszkiewicz, N; Zalewska, A; Zalewska-Szajda, B; Zwierz, K; Ładny, JR, 2012) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rocha, FF | 1 |
| Bamberg, TO | 1 |
| Pinto, FC | 1 |
| Gomes, LM | 1 |
| Silveira, S | 1 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 1 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Binbay, T | 1 |
| Waszkiewicz, N | 1 |
| Zalewska-Szajda, B | 1 |
| Szajda, SD | 1 |
| Simonienko, K | 1 |
| Zalewska, A | 1 |
| Szulc, A | 1 |
| Ładny, JR | 1 |
| Zwierz, K | 1 |
| Cordeiro, Q | 1 |
| Vallada, H | 1 |
| McElroy, SL | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Suppes, T | 1 |
| Hellemann, G | 1 |
| Black, D | 1 |
| Mintz, J | 1 |
| Kupka, R | 1 |
| Nolen, W | 1 |
| Leverich, GS | 1 |
| Denicoff, KD | 1 |
| Post, RM | 1 |
| Keck, PE | 1 |
| Benazzi, F | 1 |
1 review available for sibutramine and Bipolar Disorder
| Article | Year |
|---|---|
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
1 trial available for sibutramine and Bipolar Disorder
| Article | Year |
|---|---|
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Appetite Depressants; Bipolar D | 2007 |
6 other studies available for sibutramine and Bipolar Disorder
| Article | Year |
|---|---|
Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Cyclobutanes; Female; Humans; Obesity | 2008 |
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |
[First-episode mania with psychotic features induced by over-the-counter diet aids containing sibutramine].
Topics: Appetite Depressants; Bipolar Disorder; Cyclobutanes; Humans; Hypnotics and Sedatives; Lorazepam; No | 2010 |
Sibutramine-induced mania as the first manifestation of bipolar disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Cyclobutanes; Depressive Disorder; Female; Humans; Young Ad | 2012 |
Sibutramine-induced mania episode in a bipolar patient.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cyclobutanes; Humans; Male; V | 2002 |
Organic hypomania secondary to sibutramine-citalopram interaction.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Citalopram; Cyclobutanes; Depressive Disorder; Drug I | 2002 |